Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Marcus, S. C. Articles by Olfson, M. Search for Related Content PubMed Citation Articles by Marcus, S. C. Articles by Olfson, M. Depression Antidepressants Related Article

Antidepressant Switching Among Adherent Patients Treated for Depression

Dr. Marcus is affiliated with the School of Social Policy and Practice, University of Pennsylvania, Philadelphia. Dr. Hassan is with the Department of Health and Outcomes Research, AstraZeneca Pharmaceuticals, LP, Wilmington, Delaware. Send correspondence to Dr. Olfson, Department of Psychiatry and New York State Psychiatric Institute, Columbia University, 1051 Riverside Dr., New York, NY 10032 (e-mail: mo49{at}columbia.edu).

OBJECTIVE: This study examined the pharmacologic, clinical, and demographic factors associated with switching antidepressants during the first three months of outpatient treatment for episodes of depression. METHODS: A cohort analysis of outpatients aged 18–75 and treated for a depressive disorder (N=56,521) was performed with PharMetrics administrative data from 2001–2006. Patients commencing antidepressant treatment who continued to receive the initial antidepressant or a second antidepressant for 72 of the first 90 days were selected. Antidepressant switching was defined as prescription of a second antidepressant within 90 days of the first antidepressant prescription and continuation of the second antidepressant for 15 days after termination of the first antidepressant. RESULTS: Overall, 8.6% of patients switched antidepressants during the first 90 days of treatment. The highest rates of switching were among patients initiating trazodone (47.4%), tricyclic antidepressants (26.6%), and mirtazapine (17.2%); the lowest switching rates occurred after starting venlafaxine (6.5%) or sertraline (7.4%). Antidepressant switching was significantly related to recent emergency mental health treatment (adjusted odds ratio [AOR]=1.7, 99% confidence interval [CI]=1.3–2.2); treatment of major depressive disorder versus other depressive disorders (AOR=1.4, CI=1.3–1.5), especially severe major depressive episodes (AOR=1.6, CI=1.4–1.9); and inversely related to moderately high versus low initial antidepressant dose (AOR=.7, CI=.6–.8). Several other patient characteristics were significant but less powerful predictors of antidepressant switching. CONCLUSIONS: Among adults with depression starting antidepressant therapy, medication switching commonly occurs during the first three months of treatment. Greater clinical severity and low initial dosing may increase the risk of switching antidepressants.

Related Article:

May 2009: This Month's Highlights
Psychiatr Serv 2009 60: 579. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us